{"nctId":"NCT00848081","briefTitle":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers","startDateStruct":{"date":"2009-03"},"conditions":["Benign Prostatic Hyperplasia"],"count":318,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Tadalafil","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil"]}],"interventions":[{"name":"Tadalafil","otherNames":["LY450190","Cialis"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stable on alpha blocker therapy for the treatment of BPH for at least 4 weeks prior to starting the study.\n* Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:\n\n  1. All other Benign Prostatic Hyperplasia therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.\n  2. Overactive Bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.\n  3. Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.\n* If taking finasteride or dutasteride, must have been taking treatment for at least 6 months.\n\nExclusion Criteria:\n\n* Currently receiving alpha-blocker therapy for the treatment of hypertension.\n* History of symptoms associated with orthostasis, including recurrent episodes of dizziness, lightheadedness, loss of consciousness, or syncope.\n* Treated with nitrates for any cardiac conditions.\n* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).\n* Have problems with kidneys, liver, or nervous system\n* Have uncontrolled diabetes\n* Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (PSA greater than 10 ng/ml at the start of study).\n* Have had a stroke or a significant injury to brain or spinal cord.","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Men With Treatment-emergent Dizziness","description":"The primary safety measure is the proportion (reported in numbers) of subjects experiencing treatment-emergent dizziness to include the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of dizziness, dizziness postural, and procedural dizziness. Treatment-emergent dizziness is defined as any of the predefined terms of dizziness that is first reported or worsens in severity after baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit","description":"A positive orthostatic test is defined as at least one of the following 4 criteria being met at any pre-randomization or post-randomization visit: (1) reduction in systolic blood pressure of \\>= 20 mmHg from the supine to standing position;(2)reduction in diastolic blood pressure of \\>=10 mmHg from the supine to standing position;(3)increase in heart rate of \\>= 20 bpm from the supine to standing position; or (4)Unable to remain standing. A negative orthostatic test is defined as none of the above 4 criteria (1, 2, 3, or 4) being met at any pre-randomization or post-randomization visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"International Prostate Symptom Score (IPSS) Change From Baseline","description":"Change from baseline to endpoint in IPSS Score. The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"6.57"},{"groupId":"OG001","value":"13.87","spread":"7.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"5.29"},{"groupId":"OG001","value":"-2.28","spread":"5.65"}]}]}]},{"type":"SECONDARY","title":"Postvoid Residual Volume (PVR) Change From Baseline","description":"Change from baseline to endpoint in PVR volume. PVR is obtained by measuring with ultrasound the remaining urine in the bladder after urination.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":"74.87"},{"groupId":"OG001","value":"80.3","spread":"80.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"82.86"},{"groupId":"OG001","value":"-8.1","spread":"88.5"}]}]}]},{"type":"SECONDARY","title":"Uroflowmetry (Qmax) Change From Baseline","description":"Change from baseline to endpoint in Qmax. Qmax is defined as the peak urine flow rate (measured in milliliters per second \\[mL/second\\] using standard calibrated flowmeter).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"5.88"},{"groupId":"OG001","value":"11.8","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"4.03"},{"groupId":"OG001","value":"0.6","spread":"3.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":160},"commonTop":["Dizziness","Dyspepsia","Diarrhoea","Back pain","Gastrooesophageal reflux disease"]}}}